EyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress
May 08, 2019
|
EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2019
|
EyePoint Pharmaceuticals Announces First Quarter 2019 Financial Results Release Date and Conference Call Information
Apr 23, 2019
|
EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences
Apr 16, 2019
|
EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
Apr 02, 2019
|
EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Mar 28, 2019
|
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock
Mar 27, 2019
|
EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments
Mar 14, 2019
|
EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCU (dexamethasone intraocular suspension) 9%
Mar 12, 2019
|
EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information
Feb 14, 2019
|
EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility
Feb 13, 2019
|
EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
Feb 04, 2019
|
EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors
Jan 28, 2019
|
EyePoint Pharmaceuticals Provides 2019 Commercial Update
Jan 03, 2019
|
EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index
Dec 17, 2018
|
EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary
Nov 27, 2018
|
EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)
Nov 12, 2018
|
EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
Nov 06, 2018
|
EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments
Nov 06, 2018
|
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region
Nov 05, 2018
|